Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
Tyrosine kinase inhibitors are a new class of anticancer drugs, that are capable of directly interacting with the catalytic site of the target enzyme and thereby inhibiting catalysis. Therapeutically useful tyrosine kinase inhibitors are not specific for a single tyrosine kinase, but rather they are...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
MDPI
2010
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034030/ |